Seattle biotech Atossa Therapeutics eyes acquisition of unnamed company By: Puget Sound Business Journal (Seattle) via Business Journals July 11, 2022 at 17:25 PM EDT Atossa has paid $3 million for exclusive rights to negotiate the deal. The target company focuses on a form of cancer treatment. Read More >> Related Stocks: Harbor Disruptive Innovation ETF
